Mumbai, Oct. 31 -- The stock has fallen 4.55% in two trading sessions since the announcement.

The drug major on Thursday, 30 October 2025, announced that its MD and Global CEO, Umang Vohra, will not seek reappointment. The company stated that Achin Gupta, its current Global COO, will take over as CEO for a five-year term starting 1 April 2026. The appointment will be proposed to the shareholders for their approval. Achin has been appointed as MD & GCEO Designate from 1 January 2026.

Further, the company also announced its Q2 results on Thursday. On a consolidated basis, the drug major reported a 3.7% increase in net profit to Rs 1,353.37 crore on a 7.6% rise in total revenue from operations to Rs 7,589.44 crore in Q2 FY26 over Q2 FY25....